Search

prescription - search results

If you're not happy with the results, please do another search

1 2026

Research published in the International Journal of Drug Policy has discovered that people taking psychoactive medications and drugs for conditions such as chronic pain seem to prefer medical cannabis to other drugs, including sedatives, opioids, and antidepressants.

Many analysts have expressed worry about the use of opioids to treat chronic pain. More than 183,000 people died of prescription opioid overdoses between 1999 and 2015 in the U.S. Some research, such as a recent study that looked at states with medical cannabis laws, suggests access to medical marijuana could reduce opioid abuse. The research used survey data from 271 people registered to purchase medical cannabis. Participants answered 107 questions covering demographic data, use of cannabis, reliance on other drugs, and health history.

Survey respondents had been prescribed drugs for a range of reasons, including chronic pain, mental health conditions, and gastrointestinal issues. Overall, 63% reported using marijuana instead of prescription drugs. The most common drug class for which participants substituted cannabis was opioids, accounting for 30% of the total. Sixteen percent of participants used marijuana to replace benzodiazepines, and 12% used marijuana instead of antidepressants.

Cannabis was also a popular replacement for potentially addictive nonmedical drugs. Twenty-five percent of respondents used cannabis instead of drinking alcohol, 12% used it instead of cigarettes or tobacco, and 3% replaced illicit drugs with cannabis. The study’s authors suggest side effects, concerns about addiction, and level of safety figure prominently among the decision to use cannabis instead of other medications. Some medical marijuana users report cannabis works better than more traditional prescription medications.

The study found individuals often faced challenges to accessing medical cannabis. More than half were charged for their marijuana prescription, with 25% paying more than $300 for the prescription. Some participants still purchased marijuana from unregulated sources in spite of having a prescription.

0 1148

Prescription drug prices are still increasing, forcing consumers into more of a struggle. Some older Americans seem to be looking for a different medicine that has been more easily obtainable and legal throughout the country. Research put out on Wednesday showed that some states that legalized medical cannabis, which is common for symptoms such as anxiety or depression, saw a drop in the amount of Medicare prescriptions for drugs used to treat similar conditions as well as a decrease int he amount of spending by Medicare Part D, which covers costs for prescription drugs.

Since the prescriptions for drugs such as opioid painkillers as well as antidepressants dropped in states where cannabis can be legally obtained and used as a replacement, the researchers stated that it seems likely legalization led to a decrease in prescriptions. This is especially noted because prescriptions did not drop for medicines where marijuana can not replace the drug. The study, which was published in Health Affairs, looked at data from Medicare Part D from 2010 to 2013. This is the first study to look at whether or not legalization can impact a doctor’s clinical practice and how it affects health costs.

The results are interesting in terms of the debate as more officials are showing interest in medical cannabis. This year, Ohio, as well as Pennsylvania, passed laws allowing the drug for therapeutic reasons, making it legal in twenty-five states as well as Washington D.C. Ballots in November could increase this number; Florida and Missouri are of the states voting on the issue this autumn. A federal agency is thinking about reclassifying medical cannabis under national drug policy in order to make it more readily available. Medical marijuana saved Medicare approximately $165 million in 2013, the researchers stated. They projected that, if medical cannabis were available throughout the country, Medicare Part D spending would have dropped in the same year by nearly $470 million. That is almost fifty percent of the program’s total spending.

0 1149

American political leaders around the country are casting about for a policy response to the widespread abuse of opioid painkillers that doesn’t replicate the mistakes of past punitive approaches to drug use.
Now, Sen. Elizabeth Warren has thrown her clout into that push for solutions – and in a way that underscores the injustices of the War on Drugs over the past several decades.

Warren is asking the Centers for Disease Control and Prevention to research how medical and recreational marijuana might help alleviate the opioid epidemic. In a letter sent Monday to CDC head Dr. Thomas Friedan, Warren urged the agency to finalize its guidance to physicians on the dos and don’ts of prescribing oxycodone, fentanyl, and other popular drugs in this category.

She also went further, asking Friedan “To explore every opportunity and tool available to work with states and other federal agencies on ways to tackle the opioid epidemic and collect information about alternative pain relief options.” Those alternatives should include pot, Warren wrote. She went on the ask Friedan to collaborate with other federal health agencies to investigate how medical marijuana is or isn’t working to reduce reliance on highly addictive prescription pills, and to research

“The impact of the legalization of medical and recreational marijuana on opioid overdose deaths.” Researching marijuana is fraught for federal agencies because the drug remains a schedule 1 controlled substance, the most restrictive category within American drug law.

The classification is reserved for drugs with “No medically accepted use,” a designation that makes less and less sense as more and more states legalize marijuana for medical use.

The federal scheduling also makes it onerous for researchers to work on answering the kinds of questions Warren raised in her letter, a reality that helped drive the centrist Brookings Institute to call for the drug to be reclassified as a schedule 2 drug in a report last October – a schedule that includes prescription drugs like Adderall and Ritalin.

It’s a sign of progress compared to the mandatory minimum sentencing laws and focus on aggressive law enforcement that marked past drug panics, but it’s also got racial overtones that are hard to ignore.

Regardless of the rationale behind the shift toward more benevolent anti-drug policies related to opioids, the crisis will probably help advance the fight to loosen America’s pot laws too. The attention now being paid to opioid abuse “Has been a key factor in opening previously closed minds,” Cannabis Now notes – including Warren’s own.

Rising scrutiny of opioid use is having other, stranger effects too.
With the high-powered painkillers booming in popularity, drug makers have little need to advertise them. Super Bowl viewers were treated to a very expensive promo Sunday night for a drug designed to alleviate the constipation that heavy opioid use can cause. The drug, an AstraZeneca invention called Movantik, may be a sign that doctors are not just overprescribing opioid painkillers in general, but specifically dishing them out to the wrong kind of patients.

0 569

Dr. Sue Sisley, a psychiatrist and at one time a clinical assistant professor at Arizona University (AU), is one of the nation’s leading scientific experts on medical marijuana.

Despite her never serving in the arm forces Sisley wears or at times carries a dog tag stamped with the number “22,” as a constant reminder of how many American vets commit suicide each day—which a majority of them are suffering from post-traumatic stress disorder, according to data from the Department of Veterans Affairs.

“Even though we all realize that is a falsely low number… it is a horrific number,” Sisley said to NewsMax Health, stating that veteran suicides outnumber the national civilian average by a large number.

After leaving AU, where she received her medical degree, Sisley finally was able to gain approval from the government to commence investigative research on cannabis for PTSD.

Currently, she has teamed up with a U.S. veteran, Roberto Pickering, a former infantry Marine who was diagnosed as 100 percent disabled from PTSD in 2004.

Unlike thousands of post-9/11 veterans who have experienced fatal outcomes due to suicide, Pickering—after years of unsuccessful prescription drug use—found another way to deal with his PTSD. He began experimenting with marijuana about 10 years ago and since then has been helping other veterans.

Together, Sisley and Pickering launched the Battlefield Foundation, which provides emotional support, as well as important health and financial solutions, for vets.

Pickering outlined the foundation’s three-pronged approach to help veterans to the LA Weekly.

The first prong is emotional support in the way of sponsorship, popularized by Alcoholics Anonymous, for vets suffering from PTSD.

The second prong is medical support—offering non-opiate based relief through cannabis therapy.

This is where Sisley comes in: She and her colleagues at the Multidisciplinary Association for Psychedelic Studies (MAPS) received a grant from the government nearly two years ago to study cannabis as a treatment for veterans with PTSD.

Because of the notoriously low-quality weed provided by the government and grown at the University of Mississippi—the only facility approved by the National Institute on Drug Abuse (NIDA)—Pickering and Sisley applied for their own license to grow, but are still waiting.

Under the medical approach, primary goals include funding and raising money for clinical trials.

To that end, the Battlefield Foundation will have a for-profit brand that will invest profits back into the foundation for the research Sisley is overseeing.

Trials are definitely needed, says Sisley, even though veterans already understand that marijuana can help treat their PTSD.

“Some vets will say, ‘I don’t need your study, I already know it helps,’ but we need controlled trials and access to objective information, not just anecdotal reports,” Sisley explained. “That will help the veteran community more than anything.”

In that medical tests can cost millions, initially, veterans with access to medical marijuana under California law can report back to Sisley and her team about how marijuana works for them.

“The medical prong is all about the clinical trials; we’re developing a database that can be published,” said Sisley.

The third prong is economic assistance. The plan is to find veterans jobs in the marijuana industry or place them in positions at Pickering’s own farming facilities.

Pickering’s idea, he told Stars and Stripes, deals with crews of veterans working together for $20 an hour trimming marijuana buds for consumption.

“Vets are coming back from war, and now they have a war here in America to fight,” he said. “The enemy is suicide and an opioid epidemic, and these guys are getting healed in the very industry that’s eliminating that.”

Pickering added that military vets could go a step beyond and start their own profitable companies.

“This is medicine, and I want it to be treated as medicine and given to the masses,” Pickering said. “All I can say is, ‘Look at my life then, look at my life now.’ I want to make [cannabis] an option for all veterans, for all people, not just veterans. Sue [Sisley] is trying to give us that definitive scientific argument.”

0 1330

Moving medicinal marijuana in the front seat of your vehicle would no longer be illegal under a measure introduced in Lansing this past Thursday.

The state lawmaker who introduced the bill stated it is “ridiculous’’ that medical marijuana patients can not carry marijuana like other people carry prescription medications.

State Rep. Peter J. Lucido, an attorney from Macomb County, says those who end up getting busted for carrying marijuana usually having to pay between $400 and $500 in fines and court costs.

“Right now, we’ve got to put medical marijuana in a container and lock it in the trunk,’’ Lucido said. “If it is truly medical and we use it as medicine, do we have any other medications that we have to carry this way? It’s a discriminatory practice.

“It makes no sense to give out medical marijuana cards and force patients to put it in the trunk,’’ he continued. “My God, it’s not a gun — being a lawyer, my law firm has taken on at least a dozen of these cases.’’

House Bill 4606 would repeal a 2012 law that makes it illegal to transport or possess marijuana unless it’s in a container secured in the trunk of a vehicle. If the vehicle does not have a trunk, the marijuana has to be in a case that is not readily accessible from the interior of the vehicle. Violators face up to 93 days in jail and a fine of up to $500.

The Michigan Court of Appeals in December ruled that the 2012 marijuana transportation law conflicted with the voter-approved Michigan Medical Marijuana Act of 2008. The 2-1 ruling reversed the misdemeanor conviction of a Clinton County man, who was charged with illegal transportation of medical marijuana.

Lucido says the legislation is especially important as the state moves towards regulating medical marijuana dispensaries.

“If the state says we are going forward with this, I want to make sure we have legislation in place before the dispensaries open,’’ Lucido said.

0 638

Lexaria Announces Research on Nonsteroidal Anti-Inflammatory Drugs

Lexaria will conduct in vitro absorption studies utilizing the Company’s technology to examine improvements in absorption across human intestinal tissue, which is expected to be followed by in vivo (animal) studies to confirm the Company’s hypothesis regarding first-pass liver metabolism. The Company postulates that its technology may enable oral delivery of NSAIDs without encountering first-pass liver metabolism, which has the potential to greatly reduce corresponding liver damage.

Pain-relief drugs are comprised mostly of NSAIDs and of opioids and represented a $36.6 billion market in 2014. (MSP, BCC Research – The Global Market for Pain Management Drugs and Devices, September 2015) Long term use or overuse of NSAID’s has been associated with chronic liver conditions that can be debilitating and even cause death.

Common generic forms of NSAIDS are products such as Aspirin, Ibuprofen, Naproxen, Diclofenac and others. Acetaminophen is sometimes included within this list. More effective absorption of NSAIDS may also lead to more effective pain killing properties, thus allowing for fewer opioid medication prescriptions. Prescription based opioid medications are responsible for nearly 18,000 deaths annually in the USA. (National Institute of Health)

Lexaria has a total of 18 patents pending — including the delivery of NSAIDs — and patent applications filed in more than 40 countries worldwide.

Separately, Lexaria also announces it has received US$34,753.40 from the exercise of warrants previously granted. The stock warrants were exercised at prices of US$0.2273 and US$0.1818, for a total of 156,750 common shares being issued. All warrants are being exercised by third parties who are neither officers nor directors of the Company.

No commissions or placement fees have been paid related to the funds received from this warrant exercise. Proceeds will be used for general corporate purposes. Lexaria extends its thanks to its loyal shareholders for their continued support.

The securities referred to herein will not be or have not been registered under the United States Securities Act of 1933, as amended, and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements.

About Lexaria

Lexaria Bioscience Corp. is a food biosciences company with a proprietary technology for improved delivery of bioactive compounds. The Company’s lipophilic enhancement technology has been shown to enhance the bioavailability of orally ingested cannabinoids, while also masking taste. This technology promotes healthy ingestion methods, lower overall dosing and higher effectiveness in active molecule delivery. The Company’s technology is patent-protected for cannabidiol (CBD) and all other non-psychoactive cannabinoids, and patent-pending for Tetrahydrocannabinol (THC), other psychoactive cannabinoids, non-steroidal anti-inflammatory drugs (NSAIDs), nicotine and other molecules.

www.lexariabioscience.com

FORWARD-LOOKING STATEMENTS

This release includes forward-looking statements. Statements which are not historical facts are forward-looking statements. The Company makes forward-looking public statements concerning its expected future financial position, results of operations, cash flows, financing plans, business strategy, products and services, competitive positions, growth opportunities, plans and objectives of management for future operations, including statements that include words such as “anticipate,” “if,” “believe,” “plan,” “estimate,” “expect,” “intend,” “may,” “could,” “should,” “will,” and other similar expressions are forward-looking statements. Such forward-looking statements are estimates reflecting the Company’s best judgment based upon current information and involve a number of risks and uncertainties, and there can be no assurance that other factors will not affect the accuracy of such forward-looking statements. Factors which could cause actual results to differ materially from those estimated by the Company include, but are not limited to, government regulation, managing and maintaining growth, the effect of adverse publicity, litigation, competition, the patent application and approval process and other factors which may be identified from time to time in the Company’s public announcements and filings. Plans can change thus there is no assurance that any currently planned R&D will in fact occur, or that any R&D will provide successful or useful data or results. There is no assurance that existing capital is sufficient for the Company’s needs or that it will be able to raise additional capital. There is no assurance that Lexaria will successfully complete any other contemplated or existing technology license agreements, nor that Lexaria’s technology will deliver any improvement in taste or bioavailability with any reliability nor across any product category. There is no assurance that any planned corporate activity, business venture, or initiative will be pursued, or if pursued, will be successful. There is no assurance that any hemp oil or cannabinoid-based product will promote, assist, or maintain any beneficial human health conditions whatsoever, nor that any patent application in the USA or any other nation or under any treaty will result in the award of an actual patent; nor that an award of any actual patent will protect against challenges from unknown third parties. There is no assurance that any of Lexaria’s postulated uses, benefits, or advantages for the patent-pending technology will in fact be realized in any manner or in any part. No statement herein has been evaluated by the Food and Drug Administration (FDA)or by Health Canada. Lexaria products are not intended to diagnose, treat, cure or prevent any disease.

The CSE has not reviewed and does not accept responsibility for the adequacy or accuracy of this release.

0 863
Florida Marijuana

In the 2016 November elections, more than 72% of Floridians voted to legalize medical cannabis for people suffering from debilitating illnesses like cancer, AIDS, and Alzheimer’s.

The legislation leaves state legislators responsible for the development of a system of rules and regulations. The initial versions of legislation they were awful and included clauses like the banning of all forms of cannabis (smoking, edibles, and vaping).

Yesterday, Florida’s House of Representatives passed its own series of regulations for the state’s medical cannabis industry. These regulations are not in-line with what the people wanted but is an improvement when compared to the prior versions.

Better than Before but Flawed

The passing of these regulations has upset a lot of cannabis advocates who have been working tirelessly on moving this initiative forward.

The legislation prevents the smoking of medical cannabis and creates a state-controlled system of legal cannabis farms. It also requires doctors to provide formal prescriptions for cannabis as opposed to recommendation.

The prescription requirement cripples the legislation since cannabis is still illegal at the federal level. This means that doctors who prescribe medicinal cannabis can lose their FDA licenses.

Off to the Senate before Session Ends

The legislation will now be sent to Florida’s Senate for revisions just before the state’s 60-day legislative session ends in three days. Advocates hope for the bill to be amended by the Senate and quickly sent back to the House for approval and passing before session ends.

The Florida state Legislature does not have a great track record when it comes to taking care of tis people and we urge that people go out and support this initiative before session ends!

0 565

Pazoo, Inc. CEO Speaks at Cannabis Convention and Subsidiary MA & Associates, LLC Continues Processing Samples

Furthermore, last week on April 22 and 23, the CEO of Pazoo, David Cunic, was a guest speaker at the annual New England Cannabis Convention (NECANN) and was part of the Cannabis Investment & Entrepreneur Panel of Experts at NECANN in Boston, Massachusetts. David offered his forecast on the trajectory of the booming cannabis industry and specifically, the testing lab sector. David also addressed a key issue of varying cannabis regulations. He provided his take on the importance of establishing consistent nationwide cannabis testing requirements to a sold-out room.  By combining an efficient and cost-effective methodology, the MA team can perform the most accurate and efficient testing that is available on the market.

“Everyone at Pazoo and MA & Associates, LLC takes pride in following the stringent cannabis laboratory testing guidelines, established by the state of Nevada, to ensure every sample test is evaluated carefully so we can provide the most accurate results”, said David Cunic, CEO Pazoo. “Cannabis is a medicine, and must be used safely. It’s important that with each prescription, patients are aware of the potency so they can better select a mixture that will offer the best medical benefits for their health. With every sample, we carefully examine potency and harmful impurities, such as mold, fungus, pesticides, and more even before the product is sold at legal dispensaries in states where medical marijuana is approved.”

About Pazoo, Inc:

Pazoo, Inc. is a company focused on health, wellness and safety. Our focus is to provide best-in-class laboratory testing of cannabis and cannabinoids to protect consumers from impurities, contaminants and other irregularities. Through our wholly owned subsidiaries, Harris Lee and MA & Associates, Pazoo provides industry leading laboratory testing of cannabis. Pazoo is licensed to test cannabis in Nevada, with a focus on expansion into other states. Additionally, Pazoo delivers a comprehensive array of health and wellness information on its website www.pazoo.com, and features industry experts from both the health and wellness arena and the pet industry. Lastly, our newly formed wholly owned subsidiary CK Distribution LLC, provides the marketing and sales agent for the distribution of non-controlled hemp products throughout the USA. Non-controlled hemp products are the items utilized by the industry that support grow facilities, infusion companies and dispensaries.

Safe Harbor Statement:

This update includes forward-looking statements. These forward-looking statements generally can be identified by phrases such as Pazoo, Inc. or its management “believes,” “expects,” “anticipates,” “foresees,” “forecasts,” “estimates” or other words or phrases of similar import. Similarly, statements herein that describe the Company’s business strategy, outlook, objectives, plans, intentions or goals also are forward-looking statements. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statement.

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/pazoo-inc-ceo-speaks-at-cannabis-convention-and-subsidiary-ma–associates-llc-continues-processing-samples-300449282.html

0 2144
marijuana

Another strong day in the books for Vinergy Resources (VNNYF) as the stock gained 11% today, May 2, 2017. With this type of action, everyone should be starting to take notice and paying attention. Volume was again at record levels which could be signaling that investors are starting to act ahead of the possible completed acquisition of MJ Biopharma. VNNYF has now gained 23% since we re-initiated coverage on the company just two days ago.

As we pointed out earlier, trading for Vinergy Resources on the Canadian exchange under symbol VIN.CN has been halted pending a fundamental change in the company. Through corporate announcements and pure logic it is our assumption that the fundamental change is the completion of the MJ Biopharma acquisition. The hype and speculation that helped skyrocket Vinergy’s stock nearly 200% earlier this year (when we first initiated coverage on the company), could finally be coming to fruition. The hype that drove investors wild just a few months ago could soon be reality.

While trading of Vinergy in Canada under VIN.CN is halted, trading on the U.S. exchange through symbol VNNYF is picking up in a huge way. We have seen record volume days this week and a consistent, steady climb in share price. It would appear that momentum is in our favor as speculation once again starts to swirl around chat rooms and message boards about what the MJ Biopharma acquisition could mean for VNNYF and its shareholders. For more on why it’s significant and what investors should know about the acquisition, click here.

What a Scientific Advisory Board Addition Means for the Company’s Cannabis Initiative

Vinergy recently made a jaw dropping addition to their Scientific Advisory Board that seems to be in line with an MJ Biopharma acquisition. The company recently added John Simon, a senior member of the American Society for Quality, a certified quality auditor and registered quality assurance professional. Mr. Simon has been directly involved with FDA and Health Canada audits of drug manufacturers, testing facilities, and clinical sites.

Simon assists companies with both site and product licenses. He has helped several companies obtain, renew, and maintain in good standing Drug Establishment Licenses, Medical Device Establishment Licenses, Natural and Non-prescription Site Licenses, and Licenses to Cultivate and Distribute under the Marihuana for medical Purposes Regulations (MMPR which is now under the ACMPR).

He has extensive experience when it comes to product submissions to both the FDA and Health Canada. Simon will play a key role in driving the company’s cannabis product and technology initiatives. His work could be critical to MJ Biopharma’s long-term strategy of conducting studies out of a state-of-the-art lab focused on identifying specific cannabinoid isolates for targeted therapeutic purposes.

John Simon could be VNNYF’s bridge to the FDA and Health Canada hopefully ensuring a smooth approval and licensing process for the company. We could be speculating here a bit but it certainly seems like the addition of John Simon was carefully calculated by management and could return tremendous value for the company.

 Disclaimer: Pursuant to an agreement between MAPH and a non-affiliate third party, we were hired for a period of 1 month from 5/1/2017 – 6/1/2017 to publicly disseminate information about (VNNYF) including on the Website and other media including Facebook and Twitter. We are being paid $150,000 (CASH) for or “ZERO” shares of restricted or unrestricted common shares. We own zero shares of (VNNYF) which we purchased in the open market.We may buy or sell additional shares of (VNNYF) in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information.

0 1105

Now we all know that no one can deny that marijuana is a drug(according to federal regulation), but when used correctly it can also be a medicine. In the 28 states that have legalized medicinal marijuana over the last decade something amazing has happened, people who are on Medicaid filed for less prescriptions in those legal states. According to a new study, If medical marijuana were legalized in all 50 states, Americans could save more than a billion dollars in Medicaid costs.

It’s no big secret that cannabis can be utilized for many ailments that are associated with serious diseases like chronic pain and cancer. ( two different ailments which would require a cocktail of big-pharma medicine to treat)

seeking to enumerate the extent that marijuana, CBD oil and other marijuana-based items replace pharmaceutical medicines, researchers from Health affairs examined prescription data from Medicaid programs between 2007 and 2014. And in more than half of the clinical categories studied, the researchers found that fewer prescriptions were filled where cannabis was available.

The study found  “a 13 percent reduction for drugs used to treat depression, a 17 percent reduction for those used to treat nausea, 12 percent reductions for those used to treat psychosis and those used to treat seizure disorders, and an 11 percent reduction for drugs used to treat pain.”

“If all states had had a medical marijuana law in 2014, we estimated that total savings for fee-for-service Medicaid could have been $1.01 billion,” wrote the authors. “Our findings suggest that patients and physicians in the community are reacting to the availability of medical marijuana as if it were medicine.”

Obviously, this study only looks at data from health-care programs that include the country’s low-income healthcare program, Medicaid. Roughly 20 percent of Americans are currently on a form of Medicaid, which suggests that the annual savings in prescription drugs would be several billions more.

Subscribe Now & Begin Receiving Marijuana Stocks News, Articles, Trade Alerts & MORE, all 100% FREE!

We are your #1 source for all things Marijuana Stocks, Subscribe Below!

Privacy Policy: We will NEVER share, sell, barter, etc. any of our subscribers information for any reason ever! By subscribing you agree we can send you via email our free e-newsletter on marijuana stocks related, articles, news and trade alerts. Further questions please contact privacy@marijuanastocks.com
Ad Placements